Market capitalization | $39.21m |
Enterprise Value | $42.28m |
P/E (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | negative |
EV/Sales (TTM) EV/Sales | 41.05 |
P/S ratio (TTM) P/S ratio | 38.07 |
P/B ratio (TTM) P/B ratio | 19.63 |
Revenue (TTM) Revenue | $1.03m |
EBIT (operating result TTM) EBIT | $-49.60m |
As a Free StocksGuide user, you can view scores for all 6,780 stocks worldwide.
5 Analysts have issued a Rani Therapeutics Holdings Inc - Ordinary Shares Class A forecast:
5 Analysts have issued a Rani Therapeutics Holdings Inc - Ordinary Shares Class A forecast:
Dec '24 |
+/-
%
|
||
Revenue | 1.03 1.03 |
-
|
|
Gross Profit | - - |
-
|
|
EBITDA | -49 -49 |
25%
25%
|
EBIT (Operating Income) EBIT | -50 -50 |
25%
25%
|
Net Profit | -30 -30 |
12%
12%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Rani Therapeutics Holdings, Inc. operates as a clinical stage bio-therapeutics company providing technologies to enable the development of orally administered biologics. It offers RaniPill capsule, an orally ingestible pill for the administration of a broad range of biologics. The company was founded by Mir Imran on April 6, 2021 and is headquartered in San Jose, CA.
Head office | United States |
CEO | Talat Imran |
Employees | 105 |
Founded | 2012 |
Website | www.ranitherapeutics.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.